NVCR has 36-month beta value of 0.74. Analysts have mixed views on the stock, with 3 analysts rating it as a “buy,” 2 as “overweight,” 2 as “hold,” and 0 as “sell.”
The public float for NVCR is 98.79M, and currently, short sellers hold a 4.70% ratio of that float. The average trading volume of NVCR on June 25, 2025 was 1.10M shares.
NVCR) stock’s latest price update
The stock price of NovoCure Ltd (NASDAQ: NVCR) has jumped by 2515441 compared to previous close of 16.61. Despite this, the company has seen a fall of -5.05% in its stock price over the last five trading days. zacks.com reported 2025-06-18 that NovoCure (NVCR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
NVCR’s Market Performance
NVCR’s stock has fallen by -5.05% in the past week, with a monthly drop of -6.13% and a quarterly drop of -14.05%. The volatility ratio for the week is 2.45% while the volatility levels for the last 30 days are 4.16% for NovoCure Ltd. The simple moving average for the past 20 days is -3.45% for NVCR’s stock, with a -15.71% simple moving average for the past 200 days.
Analysts’ Opinion of NVCR
Many brokerage firms have already submitted their reports for NVCR stocks, with Evercore ISI repeating the rating for NVCR by listing it as a “Outperform.” The predicted price for NVCR in the upcoming period, according to Evercore ISI is $30 based on the research report published on December 02, 2024 of the previous year 2024.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see NVCR reach a price target of $30, previously predicting the price at $24. The rating they have provided for NVCR stocks is “Buy” according to the report published on October 16th, 2024.
JP Morgan gave a rating of “Neutral” to NVCR, setting the target price at $15 in the report published on November 20th of the previous year.
NVCR Trading at -2.99% from the 50-Day Moving Average
After a stumble in the market that brought NVCR to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -50.19% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at NVCR starting from Stafford Kristin, who sale 999 shares at the price of $17.28 back on Jun 03 ’25. After this action, Stafford Kristin now owns 3,054 shares of NovoCure Ltd, valued at $17,259 using the latest closing price.
LEUNG GABRIEL, the Director of NovoCure Ltd, sale 999 shares at $17.31 during a trade that took place back on Jun 03 ’25, which means that LEUNG GABRIEL is holding 81,229 shares at $17,297 based on the most recent closing price.
Stock Fundamentals for NVCR
Current profitability levels for the company are sitting at:
- -0.27 for the present operating margin
- 0.77 for the gross margin
The net margin for NovoCure Ltd stands at -0.26. The total capital return value is set at -0.33. Equity return is now at value -45.52, with -13.85 for asset returns.
Based on NovoCure Ltd (NVCR), the company’s capital structure generated 0.66 points at debt to capital in total, while cash flow to debt ratio is standing at -0.04.
Currently, EBITDA for the company is -108.26 million with net debt to EBITDA at -5.4. When we switch over and look at the enterprise to sales, we see a ratio of 3.96. The receivables turnover for the company is 5.24for trailing twelve months and the total asset turnover is 0.5. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.47.
Conclusion
To put it simply, NovoCure Ltd (NVCR) has had a bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
